Globe Newswire
Globe Newswire
Man Group PLC : Form 8.3 - Gamma Communications Plc
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
(a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be... (continue reading...)
Man Group PLC : Form 8.3 - RHI Magnesita N.V.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
(a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be... (continue reading...)
Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development
VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EMphora™ artificial intelligence platform to identify novel precision medicine strategies designed to accelerate... (continue reading...)
Man Group PLC : Form 8.3 - Rotork plc
#FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
(a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be... (continue reading...)
Man Group PLC : Form 8.3 - Sthree
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION
(a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be... (continue reading...)More Globe Newswire
View Older Stories-
Man Group PLC : Form 8.3 - Vesuvius Plc
-
Cash Flows
-
New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Journeys
-
New Travel Industry Coalition Calls for EU Digital Omnibus to Enable Secure, Seamless Biometric Journeys
-
Hyster hydrogen fuel cell ReachStacker supports sustainable ports project at Rotterdam Short Sea Terminals
-
Allogenetics Appoints Dr. Olaf Schermeier as Chairman of the Advisory Board
-
FTI Consulting Expands UK Turnaround & Restructuring Capabilities With Four Senior Hires
-
Contentstack Launches Contentstack Canoe, an AI Visibility Tool That Shows Brands What AI Tells Their Buyers
-
Huntress Accelerates European Expansion Through New ALSO Partnership
-
FTI Consulting Expands UK Turnaround & Restructuring Capabilities With Four Senior Hires
-
Ress Life Investments A/S publishes Net Asset Value (NAV).
-
Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
-
Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
-
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
-
Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and
-
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
-
CROSSVOLUTION Is Coming: OMODA X to Make Its Global Debut on October 20, Opening Up New Possibilities for Crossover
-
Inseego Completes Acquisition of Nokia’s Fixed Wireless Access Business
-
CallTower Transforms Its Global Communications Platform Through Acquisition of Momentum Telecom’s Voice and Collaboration Business
-
SkinHealth Systems Expands SkinStylus® SteriLock® MicroSystem to Europe
-
StoneX and Cotlook to Launch New OTC Cotton Derivatives
-
Offentliggørelse af prospekt for Investeringsforeningen Nordea Invest
-
Offentliggørelse af prospekt, Investeringsforeningen Wealth Invest
-
ICEYE and Nokia partner to launch secure and sovereign satellite communications for governments and defense customers
-
EMGA's continued success in Brazil
-
EMGA's continued success in Brazil
-
Michelin: Disclosure of trading in own shares - October 1st, 2026
-
KPN announces changes to Board of Management and Supervisory Board
-
Pulsar Helium Signs and Accepts Chart Industries Firm Proposal for Commercial-Scale Helium Liquefaction Plant
-
CompoSecure Opens New London Design Centre to Meet Growing International Demand for Premium Metal Cards
-
Kobalt Founder Willard Ahdritz Launches Ahdritz Capital Partners With Stephen Langer and Isabel Keulen
-
Vicat - Proposed Acquisition by Vicat Group of Cemex Group's Ready-Mix Concrete and Aggregates Businesses in South-Eastern France
-
2026 Nanoq Drilling Programme Completed and Initial Positive Metallurgical Test Work Results
-
Stolt-Nielsen Limited Reports Unaudited Results For the Third Quarter and Nine Months of 2026
-
Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions
-
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
-
NBPE announces Total Voting Rights
-
Total Voting Rights
-
NBPE Announces Transaction in Own Shares
-
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
-
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
-
Transaction in Own Shares
-
Total Voting Rights and Capital
-
BLOCK LISTING INTERIM REVIEW
-
DRIVING GROWTH THROUGH ADHESIVE SYSTEMS, INNOVATION, AND DIGITAL MARKET LEADERSHIP
-
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
-
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
-
Start of Day Message
-
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
-
dsm-firmenich completes €540 million share repurchase program
